MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02183402

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12
Registration Number
NCT02183532

Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02183103

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: BI 1356 BS, low dose
Drug: BI 1356 BS, medium dose
Drug: BI 1356 BS, high dose
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
77
Registration Number
NCT02183415

Tolerability of Pharmaton PHL 00747 in Healthy, Young Female Subjects of Child-bearing Potential

Phase 3
Completed
Conditions
Healthy
Interventions
Dietary Supplement: Pharmaton PHL 00747 soft gelatine capsules
Dietary Supplement: Pharmaton PHL 00747 film-coated tablets
Dietary Supplement: Placebo film-coated tablets (fct)
Dietary Supplement: Placebo soft gelatine capsules
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
203
Registration Number
NCT02183285

Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD

First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
33
Registration Number
NCT02182856

Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT02183493

Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients

Phase 3
Completed
Conditions
Migraine Disorders
Interventions
Drug: Low dose ASA
Drug: High dose ASA
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1889
Registration Number
NCT02183688

Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Merck Glucophage® high dose
Drug: Merck Glucophage® low dose
Drug: BMS Glucophage® high dose
Drug: BMS Glucophage® low dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02183571

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1356 BS - single rising dose
Drug: BI 1356 BS - multiple rising dose
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02183311
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy